Evidence map›Paper›PMID 39415842›Full record

ArticleFrontiers in pharmacology2024

Isoflurane-lipid emulsion injection as an anticonvulsant and neuroprotectant treatment for nerve agent exposure.

Jishnu K S Krishnan, John R Moffett, Narayanan Puthillathu, Erik A Johnson, Aryan M Namboodiri

Erratum issuedAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Jishnu K S Krishnan *Uniformed Services University of the Health Sciences, Anatomy, Physiology and Genetics Department and Neuroscience Program, Bethesda, MD, United States.
John R Moffett *Uniformed Services University of the Health Sciences, Anatomy, Physiology and Genetics Department and Neuroscience Program, Bethesda, MD, United States.
Narayanan PuthillathuDepartment of Chemistry and Biochemistry, Interdisciplinary Graduate Program in Biophysics, Ohio State University, Columbus, OH, United States.
Erik A JohnsonDepartment of Neuroscience, United States Army Medical Research Institute of Chemical Defense, Gunpowder, MD, United States.
Aryan M NamboodiriUniformed Services University of the Health Sciences, Anatomy, Physiology and Genetics Department and Neuroscience Program, Bethesda, MD, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We have shown that briefly inhaled isoflurane rapidly halts convulsions and protects the central nervous system (CNS) from organophosphate-induced neuronal loss when administered at 5% for 5 min, even as late as 1 h after organophosphate exposure. In the current study we investigated if an injectable form of isoflurane was as effective as inhaled isoflurane. We used a mixture of 10% isoflurane dissolved in an IV-compatible lipid-water emulsion for intravenous administration. Rats with an implanted jugular vein cannula were infused with 1,000 μL of the 10% isoflurane-lipid emulsion (ILE) mixture at a rate of 200 μL per minute, which achieved full anesthesia lasting approximately 10 min. When administered 30 min after a highly lethal dose of the organophosphate insecticide paraoxon (POX), the short-duration administration halted convulsions over the course of the study and prevented the great majority of neuronal loss as shown by Fluoro-Jade B staining (FJB). Our results indicate that injectable isoflurane is very effective for treating organophosphate poisoning, negating the need for vaporizer equipment and enabling intravenous therapy.

Indexed as

convulsant antidote for nerve agentsdrug repurposingintravenous drug administrationorganophosphate poisoningparaoxon

Identifiers

PMID39415842
PMCPMC11479933

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.